- Home
- GROW vs CGTX Comparison
GROW vs CGTX Comparison
Compare GROW & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | CGTX |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GROW | CGTX |
|---|---|---|
| Price | $2.41 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 42.1K | ★ 938.2K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $8,546,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $0.22 |
| 52 Week High | $2.78 | $3.83 |
Technical Indicators
Market Signals| Indicator | GROW | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 49.01 |
| Support Level | $2.33 | $1.44 |
| Resistance Level | $2.45 | $1.61 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 53.00 | 40.54 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.